Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV004994909 | SCV005548199 | uncertain significance | Cardiovascular phenotype | 2024-10-20 | criteria provided, single submitter | clinical testing | The p.K583N variant (also known as c.1749G>C), located in coding exon 13 of the CACNB2 gene, results from a G to C substitution at nucleotide position 1749. The lysine at codon 583 is replaced by asparagine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Labcorp Genetics |
RCV005110079 | SCV005847306 | uncertain significance | Brugada syndrome 4 | 2024-11-05 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 583 of the CACNB2 protein (p.Lys583Asn). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with CACNB2-related conditions. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |